BridgeBio Pharma (BBIO) operating margin

Operating margin · fiscal 2025
-100.0%

BridgeBio Pharma (BBIO) had an operating margin of -100.0% in fiscal 2025 (the year ended December 31, 2025). That is 160.2 percentage points higher than the -260.2% of fiscal 2024. Figures as of 17 Nov 2026, 23:49 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Operating margin, fiscal 2025
-100.0%
Change on fiscal 2024
+160.2 pts
Highest on record
-100.0%fiscal 2025
Lowest on record
-6443.6%fiscal 2023
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

BridgeBio Pharma operating margin, in more detail

Across the 7 fiscal years on record (2019–2025), the highest was -100.0% in fiscal 2025 and the lowest -6443.6% in fiscal 2023. The fiscal 2025 figure is higher than in every one of the 6 earlier fiscal years on record, whose median is -741.8%.

Gross margin was 95.8% in fiscal 2025. Net margin was -144.4% in fiscal 2025.

History · 7 fiscal years

Operating margin by fiscal year

  • Operating margin
  • Gross margin
  • Net margin

BridgeBio Pharma operating margin, year by year

BridgeBio Pharma (BBIO) operating margin by fiscal year
Fiscal yearOperating marginChangeYear endedGross marginNet margin
2025-100.0% 160.2 pts up95.8%-144.4%
2024-260.2% 6183.4 pts up98.3%-241.4%
2023-6443.6% 5840.3 pts down73.7%-6913.9%
2022-603.3% 223.8 pts up95.6%-619.7%
2021-827.1% 4924.9 pts up—-841.2%
2020-5752.0% 5095.6 pts down—-6127.9%
2019-656.4%——-711.5%

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

How to read it

It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.

Operating margin at health care companies of similar size

Operating margin of BridgeBio Pharma and comparable companies
CompanyOperating marginFiscal year
ICON ICLR12.3%2025
Jazz Pharmaceuticals JAZZ12.1%2025
Solventum SOLV7.6%2025
BridgeBio Pharma BBIO-100.0%2025
Summit Therapeutics SMMT-9024.3%2022
Glaukos GKOS-39.3%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BBIO

BridgeBio Pharma, figure by figure

BridgeBio Pharma (BBIO) overview: price, valuation and scorecardAll health care companies by market value

BridgeBio Pharma operating margin: questions and answers

What is BridgeBio Pharma's operating margin?

BridgeBio Pharma (BBIO) had an operating margin of -100.0% in fiscal 2025 (the year ended December 31, 2025). That is 160.2 percentage points higher than the -260.2% of fiscal 2024.

Is BridgeBio Pharma's operating margin high or low compared with its own history?

The fiscal 2025 figure is higher than in every one of the 6 earlier fiscal years on record, whose median is -741.8%.

What are the highest and lowest operating margin figures on record for BridgeBio Pharma?

Across the 7 fiscal years on record (2019–2025), the highest was -100.0% in fiscal 2025 and the lowest -6443.6% in fiscal 2023.

What are BridgeBio Pharma's gross and net margins?

Gross margin was 95.8% in fiscal 2025. Net margin was -144.4% in fiscal 2025.

How is BridgeBio Pharma's operating margin calculated?

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “BridgeBio Pharma (BBIO) operating margin”, data as of 17 November 2026. https://funkfolio.com/stock/BBIO/operating-margin

Underlying data: the company's filings with the SEC and Yahoo Finance.